{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:16:29Z","timestamp":1788498989281,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Kidney transplant recipients develop disorders of mineral and bone metabolism that further impair bone strength, leading to osteoporosis and a high fracture risk. However, evidence in this setting is limited. Romosozumab, a sclerostin inhibitor with both anabolic and antiresorptive effects, is an attractive option, but its use in transplant recipients, as well as its combination with denosumab, has rarely been reported. We describe two female kidney transplant recipients with severe osteoporosis and persistently high fracture risk despite long-term denosumab, in whom romosozumab (210 mg monthly) was added to ongoing denosumab for 12 months. In both patients the bone-formation markers P1NP and BAP rose early, and bone mineral density improved preferentially at the lumbar spine (Case 1\u00a0+\u00a05.9%, Case 2\u00a0+\u00a011.2%), with only modest changes at the femoral neck and total hip. Serum calcium, parathyroid hormone, 25-hydroxyvitamin D and allograft function remained stable throughout, with no clinically significant hypocalcemia, and neither patient sustained a new vertebral fracture. Adding romosozumab to ongoing denosumab thus reopened the anabolic window and improved lumbar-spine bone mineral density without compromising mineral metabolism or graft function. This combination may represent a reasonable option for carefully selected transplant recipients who continue to lose bone or to fracture despite antiresorptive therapy, pending confirmation in controlled studies.<\/jats:p>","DOI":"10.3389\/fendo.2026.1947545","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:27:18Z","timestamp":1788496038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Reopening the anabolic window \u2014 romosozumab added to ongoing denosumab for severe osteoporosis in two kidney transplant recipients"],"prefix":"10.3389","volume":"17","author":[{"given":"Simona","family":"Barbuto","sequence":"first","affiliation":[{"name":"Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mastromauro","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Zavatta","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna","place":["Bologna, Italy"]},{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Vetrano","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mistretta","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Bisceglia","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna","place":["Bologna, Italy"]},{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Comai","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"name":"Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uberto","family":"Pagotto","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna","place":["Bologna, Italy"]},{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]},{"name":"Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cianciolo","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-021-00837-0","article-title":"Bone mineral disease after kidney transplantation","volume":"108","author":"Torregrosa","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11371015","article-title":"Bone disease after kidney transplantation","volume":"11","author":"Bouquegneau","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181a6bbda","article-title":"Risk of fractures after renal transplantation in the United States","volume":"87","author":"Nikkel","year":"2009","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021081081","article-title":"Natural history of bone disease following kidney transplantation","volume":"33","author":"J\u00f8rgensen","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.12.024","article-title":"Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients","volume":"95","author":"Evenepoel","year":"2019","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000137937.44703.42","article-title":"Calcium and calcitriol prophylaxis attenuates posttransplant bone loss","volume":"78","author":"Josephson","year":"2004","journal-title":"Transplantation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000016082.70875.36","article-title":"Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study","volume":"13","author":"De S\u00e9vaux","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03410321","article-title":"Bone and mineral disease in kidney transplant recipients","volume":"17","author":"Khairallah","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.11.013","article-title":"Chronic kidney disease\u2013mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108106","article-title":"Clinical efficacy and safety of pamidronate therapy on bone mass density in early post-renal transplant period: a meta-analysis of randomized controlled trials","volume":"9","author":"Wang","year":"2014","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.11.2111","article-title":"Alendronate prevents further bone loss in renal transplant recipients","volume":"16","author":"Giannini","year":"2001","journal-title":"J Bone Miner Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000591","article-title":"Bisphosphonate use after kidney transplantation is associated with lower fracture risk","volume":"20","author":"Kahwaji","year":"2025","journal-title":"CJASN"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4283","article-title":"Bisphosphonates in kidney disease\u2014safety first","volume":"36","author":"Khairallah","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000518363","article-title":"Denosumab-induced hypocalcemia and hyperparathyroidism in de novo kidney transplant recipients","volume":"52","author":"Cianciolo","year":"2021","journal-title":"Am J Nephrol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13692","article-title":"Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial","volume":"16","author":"Bonani","year":"2016","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.4457","article-title":"Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial","volume":"37","author":"Eriksen","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X16670154","article-title":"Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis","volume":"8","author":"Langdahl","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae016","article-title":"Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study","volume":"8","author":"Adami","year":"2024","journal-title":"JBMR Plus"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000001303","article-title":"Unsolved issues in managing CKD-associated osteoporosis: myths, facts, and clinical grey zones","author":"Cianciolo","year":"2026","journal-title":"Kidney360"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-025-01590-2","article-title":"Sequential and combination therapy with romosozumab","volume":"43","author":"Kobayakawa","year":"2025","journal-title":"J Bone Miner Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease","volume":"37","author":"Miller","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.70002","article-title":"Romosozumab and denosumab combination therapy after denosumab in postmenopausal osteoporosis","volume":"78","author":"Adami","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.afos.2025.11.002","article-title":"Preliminary analysis of combined romosozumab and denosumab versus teriparatide and denosumab on bone mineral density","volume":"11","author":"Chiang","year":"2025","journal-title":"Osteoporos Sarcopenia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf211","article-title":"Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans","volume":"193","author":"Lee","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117627","article-title":"Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-na\u00efve primary osteoporosis: a retrospective cohort study","volume":"201","author":"Etani","year":"2025","journal-title":"Bone"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00319-5","article-title":"3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial","volume":"14","author":"Leder","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-026-08103-5","article-title":"Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial","author":"Kawazoe","year":"2026","journal-title":"Osteoporos Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf070","article-title":"Impact of romosozumab treatment for 24 months after switching from denosumab: three case reports","volume":"9","author":"Ahn","year":"2025","journal-title":"JBMR Plus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf049","article-title":"Romosozumab for managing severe osteoporosis in patients undergoing kidney transplantation: a retrospective case series","volume":"9","author":"Tominaga","year":"2025","journal-title":"JBMR Plus"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1947545\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:27:19Z","timestamp":1788496039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1947545\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":32,"alternative-id":["10.3389\/fendo.2026.1947545"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1947545","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1947545"}}